These data add valuable dimensions to the existing literature by providing a comprehensive understanding of the molecular mechanisms underlying NB development and offering a robust framework for risk classification by utilizing a panel of target genes rather than one single biomarker such as c-MYC or MYCN alone. The gene discussed is MYC; the disease is neuroblastoma.